Objective: Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively-activated
mutation of EGFR that contributes to the malignant progression of glioblastoma multiforme …

Amplification of epidermal growth factor receptor (EGFR) and active mutant EGFRvIII occurs
frequently in glioblastoma (GBM) and contributes to chemo/radio‐resistance in various …

The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed
in glioblastomas (GBM) but its impact on therapy response is still under controversial …

Background Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer,
and chemoresistance poses a significant challenge to the survival and prognosis of GBM …

First-line therapy for patients with glioblastoma multiforme includes treatment with radiation
and temozolomide (TMZ), an oral DNA alkylating chemotherapy. Sensitivity of glioma cells to …

Glioblastomas are characterized by amplification of EGFR. Approximately half of tumors with
EGFR over-expression also express a constitutively active ligand independent EGFR variant …

Background: Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,
exerts highly variable antiproliferative effects on human glioblastoma multiforme (GBM) cells …

Glioblastoma (GBM) is the most aggressive brain tumor in adults and remains incurable
despite multimodal intensive treatment regimens. The majority of GBM tumors show a …

Purpose: EGFR amplification and mutation (ie, EGFRvIII) are found in 40% of primary GBM
tumors and are believed to contribute to tumor development and therapeutic resistance. This …

FM 19G11 is a small molecular agent that inhibits hypoxia‐inducible factor‐1‐alpha (HIF‐
1α) and other signaling pathways. In this study, we characterized the modulating effects of …